Cannabis compounds could reverse liver disease affecting one-third of adults

A Hebrew University study published in the British Journal of Pharmacology reported that cannabidiol (CBD) and cannabigerol (CBG) reduced liver fat and improved metabolic markers in experimental models; metabolic dysfunction-associated steatotic liver disease (MASLD) affects about one-third of adults.

Researchers at Hebrew University reported laboratory findings that cannabidiol (CBD) and cannabigerol (CBG) reduced liver fat and improved metabolic health markers in experimental models. The work, published in the British Journal of Pharmacology, links these non‑intoxicating cannabis compounds to changes in cellular energy handling and waste clearance in the liver. MASLD (metabolic dysfunction‑associated steatotic liver disease) is reported to affect roughly one‑third of adults worldwide and has limited approved pharmaceutical treatments. The authors described mechanisms such as increased phosphocreatine and restored lysosomal enzyme activity as part of the observed effects, and they emphasized that the results come from controlled experimental settings. Key findings: - CBD and CBG reduced liver fat and improved metabolic markers in experimental models, as reported by the research team. - The compounds increased phosphocreatine levels, described by the authors as an energy reserve that helped the liver tolerate a high‑fat diet. - Researchers observed restored activity of cathepsin enzymes in lysosomes, aiding breakdown of harmful lipids like triglycerides and ceramides. - In some measures, CBG showed stronger effects than CBD on lowering total body fat mass, reducing LDL cholesterol, and improving insulin sensitivity. - The study was conducted in controlled experimental conditions; the authors said further clinical trials in humans are necessary to determine medical application. - A 2025 JAMA analysis of cannabis research noted gaps between public perception and high‑quality clinical evidence for many claimed benefits, which the article cited for context. Summary: The study opens a potential research path for plant‑derived cannabinoids that act on cellular energy and waste processes in the liver, which could be relevant to MASLD's large global burden. Researchers reported promising laboratory results but emphasized that clinical trials are needed to assess safety and effectiveness in people. Undetermined at this time.